ACRO Applauds Release of Cures 2.0 Draft Legislation
Washington, DC — The Association of Clinical Research Organizations (ACRO) congratulates Representatives Diana DeGette (D-CO) and Fred Upton (R-MI) on the release of the Cures 2.0 discussion draft, an update to the landmark 21st Century Cures Act. The Cures Act took significant steps to modernize the clinical trial ecosystem, and ACRO welcomes this effort to build upon that progress.
ACRO has been especially committed to increasing diversity and inclusion in clinical trials to improve outcomes for vulnerable populations, and expanding the use of safe and effective decentralized clinical trials to expand patient access and reduce barriers to participation.
“Representing companies that provide services and technologies for a majority of clinical trials worldwide, ACRO was pleased to be an information resource for the 21st Century Cures Act in 2015, and we congratulate Representatives DeGette and Upton on the release of the Cures 2.0 discussion draft,” said Doug Peddicord, ACRO’s Executive Director. “We very much look forward to providing input on key issues, including increasing diversity in clinical trials, expanding the use of patient experience and real-world data, and developing a national strategy for future pandemics.”
ACRO looks forward to working with Reps. DeGette and Upton, and their colleagues in the Senate, on advancing these solutions into law.
For further comment or press inquiries, please contact Sophia McLeod, ACRO’s Director of Government Relations, at firstname.lastname@example.org.
The Association of Clinical Research Organizations (ACRO) represents clinical research and technology companies that provide a variety of specialized tools and services to support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO works to improve the quality, efficiency, and safety of biomedical research. ACRO member companies operate in more than 100 countries across the globe and conduct or support the conduct of a majority of clinical trials across all therapeutic areas.